Guangzhou Henovcom Biosciences Co., Ltd.

Pipeline

研发管线

View Details

Business cooperation

业务合作

View Details

Contact

联系我们

View Details

ABOUT US

关于我们

Development

Leadership

Our culture

Honor

About us

Guangzhou Henovcom Bioscience Co., Ltd. was founded in 2013 by biopharmaceutical veterans with extensive experience in the US biopharmaceutical industry R&D and regulatory agencies. The founders have participated in the discovery and development of several marketed blockbuster drugs.

View Details

News and information

Capping Agent LZCap® Completes FDA Registration, Accelerating Global mRNA Development

2024-08-02

Guangzhou Henovcom Bioscience Co., Ltd. ("Henovcom") recently received confirmation from the U.S. Food and Drug Administration (FDA) for the Drug Master File (DMF) registration of its cap analog LZCap® AG (3’Acm), with the registration number 039666.

Cell Reports：LZCap® Capped Multivalent mRNA Vaccine Study Shows 100% Immune Protection-1

2024-06-24

The research indicates that the LZCap®-capped multivalent monkeypox mRNA vaccine can stimulate significant antigen-specific humoral and cellular immunity, marking another major breakthrough in vaccine development.

3rd mRNA Based Therapeutics Summit USA

2023-07-19

Venue: Boston Convention and Exhibition Center Date: Jul 26, 2023 - Jul 28, 2023 The mRNA Based Therapeutics Summit, the important, authoritative, and comprehensive premier forum, will hold its third session in Boston in July this year. Many experts and company executives in the industry will attend to introduce the latest developments in mRNA pipelines, share mRNA technology breakthroughs, and demonstrate mRNA-related products.

【Reprint】AI, mRNA vaccine...experts eye latest biomedicine trends in GZ

2023-05-30

“Currently, AI is being used to assist in the diagnosis of cancer patients’ very serious infections, organ transplantation, and situations of patients in intensive care units, as well as fungal infections of the skin, nails, and hair, as well as systemic function. Therefore, the goal is to increase both the speed and accuracy of diagnosis.” Malcolm Richardson, Chief Scientist of Richardson Bio-Tech, told GDToday during the first Guangzhou International BioPharm Conference.

Capping Agent LZCap® Completes FDA Registration, Accelerating Global mRNA Development2024-08-02 Cell Reports：LZCap® Capped Multivalent mRNA Vaccine Study Shows 100% Immune Protection-12024-06-24 3rd mRNA Based Therapeutics Summit USA2023-07-19 【Reprint】AI, mRNA vaccine...experts eye latest biomedicine trends in GZ2023-05-30